The receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168) is considered an interesting target for cancer immunotherapy, because it is a TAA expressed by a broad variety of hematological malignancies and solid tumors which is linked to tumor progression and has prognostic relevance [8–16]. Here, HMMR is linked to hematologic disorder.